目录号 | 产品详情 | 靶点 | |
---|---|---|---|
TP1935L1 | Beta Amyloid | ||
RAGE antagonist peptide acetate 是一种高级的糖基化终产物 (RAGE) 拮抗剂。 它具有抗肿瘤和抗炎活性。 它可防止 RAGE 与其几个重要的配体结合,包括 HMGB-1、S100P 和 S100A4。 | |||
T11500L | Histone Methyltransferase | ||
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) 是一种具有口服活性和高效性的 I 型蛋白精氨酸甲基转移酶 (PRMTs) 抑制剂 ,具有抗癌和抗肿瘤活性,抑制PRMT1,PRMT3,PRMT4,PRMT6,PRMT8的活性,可用于研究晚期实体肿瘤。 | |||
T6157 | Apoptosis Dehydrogenase Mitochondrial Metabolism | ||
Devimistat (6,8-Bis(benzylthio)octanoic acid) 是一种线粒体代谢抑制剂,还是一种lipoic acid 拮抗剂,能阻断线粒体能量代谢,诱导多种癌细胞凋亡。 | |||
T68316 | Liver X Receptor | ||
GAC0003A4 是一种有效的 LXR 反向激动剂,具有抗肿瘤活性,能抑制 LXR 蛋白的转录。GAC0003A4 可降解 LXRβ 蛋白,以剂量依赖性方式抑制PDAC细胞增殖。GAC0003A4 有用于研究晚期胰腺癌和其他顽固性恶性肿瘤。 | |||
T77138 | TNF | ||
Ragifilimab (INCAGN-1876),一种针对糖皮质激素诱导的TNFR相关蛋白(GITR)的单克隆抗体激动剂,适用于晚期或转移性实体瘤的研究。 | |||
T77440 | |||
Codrituzumab (GC3)是一种人源化针对 glypican-3 肝癌蛋白的抗体,可与索拉非尼联合使用来研究不可治愈的晚期肝细胞癌 (HCC) 。 | |||
T76743 | c-Met/HGFR | ||
Emibetuzumab 是一种有效的人源化二价 MET 抗体 (IgG4 型)。Emibetuzumab 具有抗肿瘤活性,对 HGF 依赖性和非依赖性 MET 通路的激活和肿瘤生长有抑制作用可用于研究晚期去势抵抗性前列腺癌。 | |||
T76761 | PDGFR | ||
Olaratumab(IMC-3G3) 是一种人源抗血小板衍生生长因子受体α (PDGFRα)单克隆 IgG1 抗体,具有抗肿瘤作用,可用于研究晚期软组织肉瘤。 | |||
TN2165 | ERK NF-κB TGF-beta/Smad | ||
Rubrofusarin gentiobioside (Rubrofusarin-6-O-beta-D-gentiobioside) 一种分离自决明子的、具有清除自由基作用的化合物。 | |||
T13741 | Others | ||
Isoviolanthin 是一种黄酮类苷类化合物,提取自铁皮石斛叶中。它能减少 TGF-β1 处理的 HCC 细胞的迁移和入侵能力,对正常细胞没有毒性影响,对转移性肝癌晚期具有潜在的研究价值。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02881 | RAGE Protein, Human, Recombinant | Human | HEK293 Cells | ||
RAGE Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 35 kDa and the accession number is A0A1U9X785.
|
|||||
TMPY-02927 | RAGE Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
RAGE Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 35.5 kDa and the accession number is A0A1U9X785.
|
|||||
TMPY-01675 | RAGE Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
RAGE Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 35.3 kDa and the accession number is Q62151-1.
|
|||||
TMPY-01716 | RAGE Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
RAGE Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 61.1 kDa and the accession number is A0A1U9X785.
|
|||||
TMPY-02030 | CD82 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.
|
|||||
TMPK-00807 | Osteopontin Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Secreted phosphoprotein 1 (SPP1) expression in TAMs isolated from lung adenocarcinoma tissues and PMA-treated THP-1 cells were measured. Macrophage polarization was identified by flow cytometric analysis. Cell migration and apoptosis were assessed by Transwell migration assays and flow cytometric analysis, respectively. SPP1 is highly expressed in tumor tissues and TAMs isolated from patients with an advanced TNM stage, and also in PMA-treated THP-1 cells.
|
|||||
TMPH-03401 | Zinc Alpha 2 Glycoprotein/AZGP1 Protein, Rat, Recombinant (His & Myc) | Rat | E. coli | ||
Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. Zinc Alpha 2 Glycoprotein/AZGP1 Protein, Rat, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 39.7 kDa and the accession number is Q63678.
|
|||||
TMPK-01045 | IL-20RA Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 Cells | ||
IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage.IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC.Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.
|
|||||
TMPK-00172 | B7-H4 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
B7-H4, also known as B7x and B7S1, is a 50-80 kDa glycosylated member of the B7 family of immunomodulatory proteins.B7-H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status .
|
|||||
TMPJ-01381 | ANXA10 Protein, Human, Recombinant | Human | E. coli | ||
Annexin A10 (ANXA10) contains four Annexin repeats and is a member of the Annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. It is reported that ANXA10 may be a clinical relevant marker for predicting outcome in both early and advanced stages of bladder cancer.
|
|||||
TMPK-00479 | AGER Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.
|
|||||
TMPK-00407 | AXL Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. AXL Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 48.7 kDa and the accession number is P30530-1.
|
|||||
TMPK-00472 | AXL Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. AXL Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 46.3 kDa and the accession number is A0A1D5Q330.
|
|||||
TMPY-01584 | PR-Set7 Protein, Human, Recombinant | Human | E. coli | ||
KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.
|
|||||
TMPK-00248 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPK-00410 | AXL Protein (Primary Amine Labeling), Human, Recombinant (hFc), Biotinylated | Human | HEK293 Cells | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. AXL Protein (Primary Amine Labeling), Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with C-hFc tag. The predicted molecular weight is 72.6 kDa and the accession number is P30530-1.
|
|||||
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
|
|||||
TMPK-00249 | TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. TRAIL R4/TNFRSF10D Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 19.4 kDa and the accession number is Q9UBN6.
|
|||||
TMPK-00408 | AXL Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Axl, a member of the TAM (Tyro3, Axl, Mer) family, and its inhibitors can specifically break the kinase signaling nodes, allowing advanced patients to regain drug sensitivity with improved therapeutic efficacy. Overexpression and activation of Axl receptor tyrosine kinase have been widely accepted to promote cell proliferation, chemotherapy resistance, invasion, and metastasis in several human cancers, such as lung, breast, and pancreatic cancers. AXL Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 48.7 kDa and the accession number is P30530-1.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|
|||||
TMPJ-00292 | CD36 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
Platelet Glycoprotein 4 (CD36) is an integral membrane glycoprotein that has multiple physiological functions. It is broadly expressed on a variety of cell types including microvascular endothelium, adipocytes, skeletal muscle, epithelial cells of the retina, breast, and intestine, smooth muscle cells, erythroid precursors, platelets, megakaryocytes, dendritic cells, monocytes/macrophages, and microglia. As a member of the scavenger receptor family, CD36 is a multiligand pattern recognition receptor that interacts with a large number of structurally dissimilar ligands, including long chain fatty acid (LCFA), advanced glycation end products (AGE), thrombospondin-1,oxidized lowdensity lipoproteins (oxLDLs), high density lipoprotein (HDL), phosphatidylserine, apoptotic cells, β amyloid fibrils (fAβ), collagens I and IV, and Plasmodium falciparuminfected erythrocytes. CD36 is required for the antiangiogenic effects of thrombospondin-1 in the corneal neovascularization assay. It plays a role in lipid metabolism and has been identified as a fatty acid translocase necessary for the binding and transport of LCFA in cells and tissues.
|
|||||
TMPJ-00379 | AOC3 Protein, Human, Recombinant (hFc) | Human | HEK293 Cells | ||
Membrane primary amine oxidase(AOC3), also known as vascular adhesion protein (VAP-1) and HPAO, this protein is a member of the semicarbazide-sensitive amine oxidase (SSAO) family. VAP-1 is a type 1 membrane-bound glycoprotein that has a distal adhesion domain and an enzymatically active amine oxidase site outside of the membrane, VAP-1 has adhesive properties, functional monoamine oxidase activity, and possibly plays a role in glucose handling, leukocyte trafficking, and migration during inflammation. This rise in metabolic products contributes to generating advanced glycation end-products and oxidative stress along with the monoamine detoxification in the organism. It is highly expressed on the endothelium of the lung and trachea, and absent from leukocytes and epithelial cells. Membrane-bound VAP-1 releases an active, soluble form of the protein, which may be conducive to increased inflammation and the progression of many vascular disorders. In particular, elevation of VAP-1 activity and the increased enzymatic-mediated deamination is proposed to play a role in renal and vascular disease, oxidative stress, acute and chronic hyperglycemia, and diabetes complications.
|
|||||
TMPY-02091 | GAD67 Protein, Human, Recombinant (His) | Human | Baculovirus Insect Cells | ||
Glutamate decarboxylase 1, also known as 67 kDa glutamic acid decarboxylase, Glutamate decarboxylase 67 kDa isoform and GAD1, is a member of thegroup II decarboxylase family. GAD1 is expressed in benign and malignant prostatic tissue and may serve as a highly prostate-specific tissue biomarker. GAD1 isoform3 is expressed in pancreatic islets, testis, adrenal cortex, and perhaps other endocrine tissues, but not in brain. Tissue-specific markers are useful for identification of tumour type in advanced cancers of unknown origin. In plants, as in most eukaryotes, glutamate decarboxylase catalyses the synthesis of GABA. Root-specific calcium/calmodulin-regulated GAD1 plays a major role in GABA synthesis in plants under normal growth conditions and in response to stress. Defects in GAD1 are the cause of cerebral palsy spastic quadriplegic type 1 (CPSQ1)which is a non-progressive disorder of movement and/or posture resulting from defects in the developing central nervous system. Affected individuals manifest symmetrical, non-progressive spasticity and no adverse perinatal history or obvious underlying alternative diagnosis.
|
|||||
TMPJ-01137 | MIA Protein, Human, Recombinant (His) | Human | E. coli | ||
Melanoma Inhibitory Activity Protein (MIA) is an autocrine growth regulatory protein secreted from chondrocytes and malignant melanoma cells, which was the first discovered member of a family of secreted cytokines termed the MIA/OTOR family. The four known members of this family: MIA, MIA2, OTOR and TANGO each contain a Src homology-3 (SH3)-like domain. MIA acts as a potent tumor cell growth inhibitor for malignant melanoma cells and some other neuroectodermal tumors, including gliomas, in an autocrine fashion and promotes melanoma metastasis by binding competitively to fibronectin and laminin in a manner that results in melanoma cell detachment from the extracellular matrix in vivo. The protein MIA has been shown to represent a very sensitive and specific serum marker for systemic malignant melanoma that might be useful for staging of primary melanomas, detection of progression from localized to metastatic disease during follow-up, and monitoring therapy of advanced melanomas. Elevated levels of MIA may represent a clinically useful marker for diagnosis of melanoma metastasis as well as a potential marker for rheumatoid arthritis.
|
|||||
TMPY-01992 | Kallikrein 8/KLK8 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Kallikrein-8, also known as Neuropsin, Serine protease 19, Serine protease TADG-14, Tumor-associated differentially expressed gene 14 protein, and KLK8 is a secreted protein that belongs to the peptidase S1 family and Kallikrein subfamily. It is a serine protease that is capable of degrading some proteins such as casein, fibrinogen, kininogen, fibronectin, and collagen type IV. Kallikrein-8 / KLK8 plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway. It regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. It is involved in skin desquamation and keratinocyte proliferation and plays a role in the secondary phase of pathogenesis following spinal cord injury. It also cleaves L1CAM in response to increased neural activity. It induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Kallikrein-8 / KLK8 is expressed at high levels in serum, ascites fluid, and tumor cytosol of advanced-stage ovarian cancer patients and may serve as a marker of ovarian cancer. Kallikrein-8 / KLK8 may have potential clinical value for disease diagnosis or prognosis and it may also be a useful therapeutic target.
|
|||||
TMPY-00924 | SMAC Protein, Human, Recombinant (His) | Human | E. coli | ||
Apoptosis is an essential processes required for normal development and homeostasis of all metazoan organisms. Second Mitochondria-Derived Activator of Caspases (Smac) or Direct IAP Binding Protein with low isoelectric point, pI (Diablo) is a proapoptogenic mitochondrial protein that is released to the cytosol in response to diverse apoptotic stimuli, including commonly used chemotherapeutic drugs. The current knowlege about structure and function of Smac/Diablo during programmed cell death, both in mitochondrial and receptor pathways are presented. It has been shown that Diablo mainly interacts with IAPs in the cytochrome c/Apaf-1/caspase-9 pathway, and promotes apoptosis. Diablo is released from the mitochondria into the cytosol occurring downstream of cytochrome c release in response to apoptotic stimuli such as irradiation, DNA damage or cytotoxic drugs. In the cytosol, Smac/Diablo interacts and antagonizes inhibitors of apoptosis proteins (IAPs), thus allowing the activation of caspases and apoptosis. This activity has prompted the synthesis of peptidomimetics that could potentially be used in cancer therapy. The role of Smac/DIABLO in colorectal carcinogenesis is ill defined. Data continues to accumulate to suggest that decreased levels of Smac/DIABLO may be important in chemoradiation-resistance to apoptosis in advanced colon cancer.
|